TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received treatment for asthma in the year prior to study entry~* Received at least one respiratory medication at a Kaiser Permanente Northwest (KPNW) or Kaiser Permanente Hawaii (KPH) outpatient pharmacy in the year prior to study entry~* Continuous Kaiser Permanente membership from the year prior to study entry through study entry~* Willing to participate in the study~Exclusion Criteria:~* Excluded from primary analyses if fewer than three months of follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Automated Phone-Based Refill Reminders (Type: EXPERIMENTAL): Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
- Usual Care (Type: NO_INTERVENTION): Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in Infants With Gastroschisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gastroschisis~* Born at or transferred to UC Davis Children's hospital~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Weeks
- Healthy Volunteers: f

Study Arms:
- Bifidobacteria infantis (Type: ACTIVE_COMPARATOR): 1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
- Placebo (Type: PLACEBO_COMPARATOR): A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histological or cytological documented~* Resectable NSCLC of stage IIIA-N2 confirmed by mediastinoscopy or PET~* Naive therapy NSCLC~* Candidates should be tolerated with induction therapy and thoracotomy with ECOG performance status 0-2, adequate haematological and Hepatic- renal function and qualified lung function~* Enough tissue samples to perform gene analysis~Exclusion Criteria:~* Small cell lung cancer~* Pregnant or breast-feeding women~* Any unstable systemic disease~* Patients with exposure to investigational drug therapy or other concurrent anticancer therapy outside of this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
- B (Type: ACTIVE_COMPARATOR): Non-erlotinib targeted NSCLC population based on EGFR gene analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of prostate adenocarcinoma.~* Patient must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy.~* Serum testosterone \< 50 mg/ml.~* Patients who have previously received docetaxel must meet BOTH of the the following criteria:~  * reason for docetaxel discontinuation must NOT have been progression of disease while receiving drug (i.e. progression of cancer must have been AFTER docetaxel discontinuation) AND~ * All docetaxel-related toxicities must have resolved to \< grade 1 (with the exception of alopecia) and the pt must be eligible by other criteria~Exclusion Criteria:~* Use of red blood cell or platelet transfusions within 4 weeks of treatment.~* Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.~* Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton (superscan).~* Prior radiation therapy encompassing \>25% of skeleton.Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).~* Platelet count \<150,000/mm3.~* Absolute neutrophil count (ANC) \<2,000/mm3.~* Hematocrit \<30 percent or Hemoglobin \< 10 g/dL.~* Abnormal coagulation profile (PT or INR, PTT) \> 1.3 x upper limit of normal (unless on therapeutic anticoagulation).~* -Serum creatinine \>2.5 mg/dL.~* AST (SGOT) \>2.5x ULN.~* Bilirubin (total) \>1.5x ULN.~* Serum calcium \>11 mg/dL.~* Active serious infection.~* Active angina pectoris or New York Heart Association Class III-IV.~* ECOG Performance Status \>2.~* Life expectancy \<6 months.~* Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.~* Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.~* Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.~* Prior investigational therapy within 6 weeks of treatment.~* Known history of HIV.~* Known history of myelodysplastic syndrome or leukemia

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 (Type: EXPERIMENTAL): 177Lu-J591 at 20 mCi/dose
- Dose Level 2 (Type: EXPERIMENTAL): 177Lu-J591 at 25 mCi/dose
- Dose Level 3 (Type: EXPERIMENTAL): 177Lu-J591 at 30 mCi/dose
- Dose Level 4 (Type: EXPERIMENTAL): 177Lu-J591 at 35 mCi/dose
- Dose Level 5 (Type: EXPERIMENTAL): 177Lu-J591 at 40 mCi/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Prenatal Coparenting Intervention (CoparentRCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~An applicant is considered eligible if the pregnancy is the mother's first with the baby's father; the mother and father are unmarried; and reported income places at or below the county and state poverty line. The target population is African American, but mixed race parents may also enroll so long as at least one parent is African American. Minor parents will be recruited only if legally emancipated or with consent of their parent or guardian (with an exception allowed if minor parent is estranged from parent or LAR). If a potential participant reports a prior history of IPV, s/he may still be eligible for participation pending a more detailed assessment completed by trained project staff using the Danger Assessment Scale (Campbell, 2003).~Exclusion Criteria:~Families are excluded if either partner 1) has recently (within the past year) been arrested and convicted for violence (assault) perpetrated against someone other than a current or former partner who is the co-parent of one of their children; 2) demonstrates evidence of psychotic symptoms or suicidal ideation on the Brief Symptom Inventory; or 3) is deemed high risk or in need of more intensive intervention. Risk determination is made by weighing the parent's report on the Danger Assessment Scale (DAS). As a rule of thumb, DAS scores of 9 or higher result in automatic exclusion from the study. However, even with a score below 9, a parent may disclose one or more of the following issues during administration of the DAS - any of which would result in exclusion from the study: 1) parent reports requiring medical care because of significant injuries due to partner's violence, 2) parent says she fears for her life, 3) parent reports that the partner has threatened with a weapon and owns a gun or has a gun in the household; 4) parent reports that the partner has threatened to kill her; 5) parent reports that violence has escalated recently; 6) parent reports the partner's use of illicit drugs such as cocaine, methamphetamines, hallucinogens, or opiates.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Intervention: Treatment as Usual + Focused Coparenting Consult (Type: EXPERIMENTAL): Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
- Control: Treatment as Usual (Type: NO_INTERVENTION): Receipt of TAU/Resource and Referral supports

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or above~* Acute stroke due to spontaneous ICH confirmed by clinical history \& CT scan~* At least 2 systolic BP measurements of \>/=150mmHg and \</=220mmHg, recorded 2 or more minutes apart~* Able to commence randomly assigned BP lowering regimen within 6 hours of stroke onset~* Able to be actively treated and admitted to a monitored facility e.g. HDU/ICU/acute stroke unit~Exclusion Criteria:~* Known definite contraindication to an intensive BP lowering regimen~* Known definite indication for intensive BP lowering regimen as (or more) intensive than the active treatment arm~* Definite evidence that the ICH is secondary to a structural abnormality in the brain~* Previous ischaemic stroke within 30 days~* A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria~* Known advanced dementia or significant pre-stroke disability~* Concomitant medical illness that would interfere with outcome assessments and follow up~* Already booked for surgical evacuation of haematoma~* Previous participation in this trial or current participation in another investigational drug trial~* A high likelihood that the patient will not adhere to the study treatment and follow up regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Survey of Inhibitors in Plasma-Product Exposed Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects~* Any ethnicity~* Age \<6 years~* Severe haemophilia A (FVIII:C \<1%), as confirmed at enrolment by the central laboratory.~  o Those patients diagnosed locally as severe but subsequently found to have FVIII levels \>= 1% on testing at the central laboratory will be separately recorded in the screening list.~* Previously untreated (0 EDs to any FVIII concentrates or blood products) or minimally treated (\<5 EDs) with blood components, namely whole blood, fresh frozen plasma, packed red blood cells, platelets or cryoprecipitate.~  o Patients not meeting these criteria will be separately recorded in the screening list.~* Negative inhibitor measurement at both local and central laboratory at screening~* Ability to comply with study requirements~* Signed informed consent of legal tutors o Patients who will not accept to enter into the study or to be randomized will be separately recorded.~Exclusion Criteria:~* Previous history of FVIII inhibitor~* Other congenital or acquired bleeding defects~* Plasma FVIII level \>= 1%, as assayed at the central laboratory~  o Those patients originally diagnosed locally as severe but subsequently found to have FVIII levels ranging from 1% to 2% on testing at the central laboratory will be separately recorded in the screening list.~* Concomitant congenital or acquired immunodeficiency~* Concomitant treatment with systemic immunosuppressive drugs~* Concomitant treatment with any investigational drug

- Gender: MALE
- Minimum Age: 1 Minute
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- PLASMA DERIVED Factor VIII (Type: ACTIVE_COMPARATOR): Plasma-derived vWF/FVIII
- rFVIII (Type: ACTIVE_COMPARATOR): Recombinant FVIII

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males, 18 or older~* proven advanced prostate cancer~* documented metastatic disease~* rising PSA levels~* castrate levels of testosterone~Exclusion Criteria:~* symptomatic CNS (brain or spinal cord) metastasis~* medical condition which may increase the risk of toxicity~* any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents~* unable to take oral medication

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-strain Probiotic in the Management of IBS-D

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed case of IBS using Rome III criteria~2. Absence of red flag sign: anemia, fever, wt loss, per rectal bleeding, nocturnal frequency, family history of inflammatory bowel disease (IBD), cancer~3. Age 18-55 years~4. No probiotics used in prior 3 months.~5. Agreed not to start any other drug unless clinically indicated.~6. No antibiotics in previous 2 months of enrolment.~Exclusion Criteria:~1. Age\<18 or \>55 years~2. Previous treatment with probiotics within last 3 months~3. Pregnant or lactating females~4. Concurrent severe illness (Uncontrolled diabetes mellitus, Renal Dysfunction, Liver disease, hyper and hypothyroidism)~5. Chronic organic bowel disorders e.g. inflammatory bowel diseases, tuberculosis, Diverticular disease etc~6. Any previous gastrointestinal surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- To assess the effect of multistrain probiotics on abdominal (Type: PLACEBO_COMPARATOR): To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
- To assess the efficacy of a multistrain probiotic supplement (Type: PLACEBO_COMPARATOR): To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* metastatic RCC with majority (\>50%) of conventional clear-cell type;~* prior total nephrectomy for primary RCC;~* at least one measurable or non-measurable lesions;~* ECOG performance score of 0 or 2.~Exclusion Criteria:~* prior systemic treatment for metastatic RCC;~* current or previously treated but non-stable CNS metastases or spinal cord compression;~* major surgery (including open biopsy) or radiation therapy within 28 days prior to enrollment;~* significant cardiovascular disease within 6 months prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-55~* Relapsing-Remitting Multiple Sclerosis (RRMS)~* Avonex therapy for 6 months prior continuous~* annualized relapse rate \>2 during Avonex therapy~* most recent relapse within 60 days of baseline~* entry Expanded Disability Status Scale (EDSS) 1.5-4.5~* one or more gadolinium (Gd+) MRI lesions on a baseline MRI~* no history of immune modulator or immunosuppressant therapy used in combination with Avonex (other then GSC administer for clinical relapses)~* not participating in any other study of ms therapeutics~* Serum neutralizing antibodies (NABs) titer to Avonex \<20~Exclusion Criteria:~* Medical or Psychiatric conditions that will affect patients ability to provide informed consent~* inability to undergo MRI~* clinically serious medical conditions or significantly abnormal labs~* no use of these medications or procedures within six months prior to study:~  \*monoclonal antibodies,total lymphoid radiation,systemic steroids,cytotoxic or immunosuppressive medications such as mitoxantrone or cyclophosphamide or any other investigational drugs~* Interferon neutralizing antibody titers \>20~* no breast feeding or pregnant~* no patients with any systemic illness,psychiatric condition or other disorder that would concern safety of patient to complete procedures of protocol~* abnormal blood test~* clinically significant abnormality on chest x-ray (CXR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Interferon beta 1a, oral doxycycline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Short Laryngologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for short, non-laser laryngologic surgery~Exclusion Criteria:~1. Patients with significantly decreased myocardial function (ejection fraction \< 50%)~2. Patients with abnormal cardiac rhythm and conduction abnormalities, except for patients with isolated, asymptomatic premature atrial and ventricular contractions.~3. Patients with significant peripheral vascular disease, such as those with the symptoms of intermittent claudication.~4. Patients with known significant cerebrovascular disease, such as history of cerebrovascular accidents (CVAs) and transient ischemic attacks (TIAs).~5. Patients with significant renal insufficiency, as manifested by estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73 m2.~6. Patients with electrolyte (K+, Ca++) abnormalities, as determined by the lab values outside of a normal range.~7. Patients with the history or symptoms of increased intracranial pressure or reduced intracranial compliance (e.g. headaches, nausea and vomiting, visual changes, mental changes).~8. Patients with skull base defects.~9. Patients with pulmonary hypertension who have pulmonary artery pressures above the normal range.~10. Patients with significant chronic obstructive or restrictive lung diseases, as manifested by known history of baseline chronic hypoxia and/or hypercapnia, and/or baseline room air SpO2 \< 95%.~11. Obese patients with BMI above 35 kg/m2.~13. Patients with severe and poorly controlled gastroesophageal reflux disease despite medical treatment.~14. Patients with hiatal hernia and full stomach patients. 15. Patient's refusal to participate in the study. 16. Patients who do not understand English or mentally handicapped. 17. Pregnant or breastfeeding patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- THRIVE (Type: EXPERIMENTAL): high flow nasal oxygen
- Endotracheal tube (Type: ACTIVE_COMPARATOR): tracheal intubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete